29 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26248802	46	Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability.	Syntrix Biosystems
25933594	6	Boronic acid-containing CXCR1/2 antagonists: Optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model.	Syntrix Biosystems
25254640	64	Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic Acid (SX-517): Noncompetitive Boronic Acid Antagonist of CXCR1 and CXCR2.	Syntrix Biosystems
23437772	35	Colloidal aggregation causes inhibition of G protein-coupled receptors.	University Of North Carolina At Chapel Hill
22931505	69	Chemokine receptor antagonists.	National Heart And Lung Institute
17181143	31	Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.	Schering-Plough Research Institute
15357956	11	Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor.	Glaxosmithkline
21341682	37	Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.	Telik
20297846	33	Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.	Genzyme
19713110	27	Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists.	Wuxi Pharmatech
19525110	46	Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.	Schering-Plough Research Institute
19560921	28	Structure-Activity Relationship of novel phenylacetic CXCR1 inhibitors.	Grupo Uriach
19200721	50	3,4-Diamino-1,2,5-thiadiazole as potent and selective CXCR2 antagonists.	Schering-Plough Research Institute
19196511	42	Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.	Schering-Plough Research Institute
10843593	3	Polyoxygenated dysidea sterols that inhibit the binding of [I125] IL-8 to the human recombinant IL-8 receptor type A.	Griffith University
18242983	82	Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.	Schering-Plough Research Institute
18006311	40	3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.	Schering-Plough Research Institute
17524641	69	3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.	Glaxosmithkline
17459706	42	C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.	Schering-Plough Research Institute
16934456	36	N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.	Glaxosmithkline
15771462	125	Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.	Pharmaceutical Research Institute
15261292	28	Synthesis and structure-activity relationships of 3,5-diarylisoxazoles and 3,5-diaryl-1,2,4-oxadiazoles, novel classes of small molecule interleukin-8 (IL-8) receptor antagonists.	Johnson And Johnson Pharmaceutical Research And Development
14998320	16	Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.	Glaxosmithkline
12031332	27	Nicotinanilides as inhibitors of neutrophil chemotaxis.	Celltech R&D
16950396	13	Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.	Osaka University Of Pharmaceutical Sciences